Floatz logo

Raloxifene

Schizoaffective Disorder

Iris SommerSmall moleculePhase 4 / ApprovedDormant
BBB
77/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
75/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the Schizoaffective Disorder cohort.

Asset / SponsorPhaseRating
Paliperidone
Luye Pharma Group Ltd.
Phase 4BBB
QUETIAPINE
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 4BBB
Olanzapine
The Royal Ottawa Mental Health Centre
Phase 4BBB
Lurasidone
University of Texas Southwestern Medical Center
Phase 4BBB
Dexmedetomidine
BioXcel Therapeutics Inc
Phase 4BBB

View all 50 →

Same molecule, other indications

Raloxifene is also rated in:

schizophreniform disorderDormant
A
Indicative · Phase 4
83 / 100
View asset →
schizophreniaDormant
BBB
Indicative · Phase 4
73 / 100
View asset →
major depressive disorderDormant
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →